Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02216409 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Trial of Hu5F9-G4, a CD47-targeting Antibody
A Phase 1 study of Solid Tumor, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 88
- Enrollment target
- 6
- Study locations
NCT02216409 is a Phase 1 study of Solid Tumor that has completed, run by Gilead Sciences. The registered enrollment target is 88 participants, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (60% lower). The trial reports 6 study locations across 6 states.
The verdict
NCT02216409, a Phase 1 study of Solid Tumor, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 88 participants
- Enrollment target
- 6
- Study locations
Study Summary
The purpose of this study is to assess the safety and tolerability of Hu5F9-G4 in participants with solid tumors.
Conditions Studied
Interventions
- DRUG Hu5F9-G4
Study Locations (6)
California
- Stanford Cancer Institute - Stanford
Illinois
- University of Chicago - Chicago
Michigan
- START Midwest - Grand Rapids
New York
- Memorial Sloan-Kettering Cancer Center - New York
Oklahoma
- University of Oklahoma - Oklahoma City
Texas
- South Texas Accelerated Research Therapeutics - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 88 participants |
| Start Date | 2014-08 |
| Est. Completion | 2018-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02216409
The ClinicalTrials.gov registry entry for NCT02216409 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 88 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (60% lower). The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which Hu5F9-G4 is the first listed.
NCT02216409 reports 6 study locations spanning 6 distinct geographic areas - top geographies include California, Illinois, Michigan.
Frequently Asked Questions
What is clinical trial NCT02216409 about?
NCT02216409 is a clinical study titled "Phase 1 Trial of Hu5F9-G4, a CD47-targeting Antibody". The purpose of this study is to assess the safety and tolerability of Hu5F9-G4 in participants with solid tumors.
What is the current status of trial NCT02216409?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 88 participants. The study started on 2014-08. Estimated completion is 2018-12.
What conditions does trial NCT02216409 study?
This clinical trial studies the following conditions: Solid Tumor.
What interventions are being tested in trial NCT02216409?
The interventions under investigation include: Hu5F9-G4 (DRUG).
Who is sponsoring clinical trial NCT02216409?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02216409 being conducted?
This trial has 6 study locations across California, Illinois, Michigan, New York, Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
-
Concurrent Azeliragon With Craniospinal Irradiation
RECRUITING · Phase 1
-
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
RECRUITING · Phase 1
-
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.